Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of SGX302 in Mild-to-Moderate Psoriasis
NCT05442190Phase 2Completed
- Sponsor
- Soligenix
- Start
- Dec 2022
- Primary completion
- Oct 2025
- Modality
- Transdermal Patches, Hydrogel Systems, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of hypericin in plaque psoriasis, sponsored by Soligenix. Started Dec 2022; status: completed.
02
Drugs
hypericin
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05442190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05442190.